FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	$D \subset$	20549	
vasiliigton,	D.C.	20549	

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Fitzpatrick Alexander A</u>				2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]										all app	tor		10% O	wner	
(Last)	`	irst) (I	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/28/2023									X	X Officer (give title Other (sp below) Chief Legal Officer				
11682 EL CAMINO REAL, SUITE 120				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)							
(Street)	EGO C	A 9	2130											X	X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(5	tate) (2	Zip)		Rul	Rule 10b5-1(c) Transaction Indication													
Check this box to indicate that a transaction was made pursuant to a contrasatisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction																			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution		tion D	ate,			s Acquired (A) o f (D) (Instr. 3, 4 a		and 5) Secur Benef		cially I Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	(A) or (D)	Price	Tran		ction(s) 3 and 4)			(11150.4)		
Common Stock 09/28/2				09/28/2	023				P		40,000	A	\$3.62	24 ⁽¹⁾	42,969 ⁽²⁾			D	
Common Stock 09/29/2			09/29/2	023			P		46,258	A	\$3.78	33 ⁽³⁾	3 ⁽³⁾ 89,227		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversior or Exercise Price of Derivative Security		if any	eemed Ition Date, h/Day/Year)	4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	6. Date Exercisable ar Expiration Date (Month/Day/Year) Date Exercisable Expirati		ate (fear)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) Amount or Number of Title Shares		Der Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	,	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from \$3.60 to \$3.64, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
- 2. Includes 2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2023.
- 3. The price reported in Column 4 is the weighted average price. The shares were purchased in multiple transactions at prices ranging from \$3.70 to \$3.85, inclusive. Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

Remarks:

<u>/s/ Alexander Fitzpatrick</u>

** Signature of Reporting Person Date

10/02/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.